keyword
https://read.qxmd.com/read/38500864/neoadjuvant-chemohormonal-therapy-before-radical-prostatectomy-in-high-risk-prostate-cancer-a-mini-review
#21
REVIEW
Junjie Fan, Zhangdong Jiang, Guojing Wang, Dalin He, Kaijie Wu
High-risk localized prostate cancer (PCa) has the potential of recurrence and progression to a lethal phenotype, and neoadjuvant therapy followed by radical prostatectomy (RP) may be an option for these patients. Docetaxel has been recently shown to be an effective chemotherapeutic agent for high-volume metastatic hormone-sensitive PCa and metastatic castration-resistant PCa, and these increased efficacy create the impetus to assess the potential role of preoperative docetaxel in high-risk localized PCa. In this mini-review, we found that neoadjuvant chemohormonal therapy (NCHT) may be an effective neoadjuvant regimen to improve oncological outcome of high-risk PCa...
2024: American Journal of Clinical and Experimental Urology
https://read.qxmd.com/read/38494380/systemic-and-tumor-directed-therapy-for-oligorecurrent-metastatic-prostate-cancer-saturn-primary-endpoint-results-from-a-phase-2-clinical-trial
#22
JOURNAL ARTICLE
John Nikitas, Matthew Rettig, John Shen, Robert Reiter, Alan Lee, Michael L Steinberg, Luca F Valle, Ankush Sachdeva, Tahmineh Romero, Jeremie Calais, Johannes Czernin, Nicholas G Nickols, Amar U Kishan
Nearly all men with metastatic hormone-sensitive prostate cancer treated with intermittent androgen deprivation therapy (ADT) experience recurrence within 6 mo of testosterone recovery. We conducted a single-arm phase 2 trial to evaluate whether addition of dual androgen receptor pathway inhibitors (ARPIs) and metastasis-directed stereotactic body radiotherapy (SBRT) to intermittent ADT improves recurrence rates for men with between one and five nonvisceral, extrapelvic metastases on prostate-specific membrane antigen positron emission tomography/computed tomography after prior radical prostatectomy...
March 16, 2024: European Urology
https://read.qxmd.com/read/38491207/extraperitoneal-robot-assisted-laparoscopic-prostatectomy-with-versius-system-single-centre-experience
#23
JOURNAL ARTICLE
F Dibitetto, C Fede Spicchiale, R Castellucci, S Sansalone, A Akhundov, L Defidio, M De Dominicis
INTRODUCTION: Versius Surgical System (CMR Surgical, Cambridge, UK) is a novel tele-operated robotic surgical system designed to assist surgeons for minimally invasive surgery which is gaining momentum in the world of robotic surgery. We describe our single centre experience with Versius and report the advantages and challenges posed by this new robotic system in a series of 53 extraperitoneal robotic assisted laparoscopic prostatectomies (eRALP) for prostate cancer (PCa). MATERIALS AND METHODS: Data of 53 eRALP performed with Versius in our centre were collected and analysed, Descriptive statistics were used to report our results...
March 15, 2024: Prostate Cancer and Prostatic Diseases
https://read.qxmd.com/read/38490923/contemporary-risk-of-biochemical-recurrence-after-radical-prostatectomy-in-the-active-surveillance-era
#24
JOURNAL ARTICLE
Sanjay Das, Michael Luu, Martha Terris, Zachary Klaassen, Christopher J Kane, Christopher Amling, Matthew Cooperberg, Lourdes Guerrios Rivera, William Aronson, Stephen J Freedland, Timothy J Daskivich
OBJECTIVES: To assess whether contemporary risks of biochemical recurrence (BCR) after radical prostatectomy (RP) in the AS era differ from historical estimates due to changes in tumor risk case mix and improvements in risk stratification. MATERIALS AND METHODS: We sampled 6,682 men who underwent RP for clinically localized disease between 2000 and 2017 from the VA SEARCH database. Kaplan Meier analysis was used to calculate incidence of BCR before and after 2010 overall and within tumor risk subgroups...
March 14, 2024: Urologic Oncology
https://read.qxmd.com/read/38490854/long-term-outcomes-and-patterns-of-relapse-following-high-dose-elective-salvage-radiotherapy-and-hormone-therapy-in-oligorecurrent-pelvic-nodes-in-prostate-cancer-oligopelvis-getug-p07
#25
JOURNAL ARTICLE
Loig Vaugier, Cyrille Morvan, David Pasquier, Xavier Buthaud, Nicolas Magné, Veronique Beckendorf, Paul Sargos, Gilles Crehange, Pascal Pommier, Genevieve Loos, Ali Hasbini, Igor Latorzeff, Marlon Silva, Julie Paul, Audrey Blanc-Lapierre, Stéphane Supiot
Androgen deprivation therapy (ADT) is a mainstay of treatment for metastatic prostate cancer, while additional salvage radiotherapy may offer prolonged remission for patients with regional node relapses. We report 5-yr outcomes from OLIGOPELVIS (GETUG-P07), an open-label phase 2 trial assessing long-term outcomes and patterns of relapse after 6-mo ADT and elective nodal radiotherapy (ENRT) in men with pelvic nodal oligorecurrence (<6 lesions) of prostate cancer. Progression was defined as two consecutive prostate-specific antigen (PSA) levels above the level at inclusion and/or clinical progression according to Response Evaluation Criteria in Solid Tumors v1...
March 14, 2024: European Urology
https://read.qxmd.com/read/38490329/chromatin-activation-with-h3k36me2-and-compartment-shift-in-metastatic-castration-resistant-prostate-cancer
#26
JOURNAL ARTICLE
Sanji Kanaoka, Atsushi Okabe, Manato Kanesaka, Bahityar Rahmutulla, Masaki Fukuyo, Motoaki Seki, Takayuki Hoshii, Hiroaki Sato, Yusuke Imamura, Shinichi Sakamoto, Tomohiko Ichikawa, Atsushi Kaneda
Epigenetic modifiers are upregulated during the process of prostate cancer, acquiring resistance to castration therapy and becoming lethal metastatic castration-resistant prostate cancer (CRPC). However, the relationship between regulation of histone modifications and chromatin structure in CRPC has yet not fully been validated. Here, we reanalyzed publicly available clinical transcriptome and clinical outcome data and identified NSD2, a histone methyltransferase that catalyzes H3K36me2, as an epigenetic modifier that was upregulated in CRPC and whose increased expression in prostate cancer correlated with higher recurrence rate...
March 13, 2024: Cancer Letters
https://read.qxmd.com/read/38485277/strong-correlation-between-suv-max-on-psma-pet-ct-and-numeric-drop-in-%C3%AE-probe-signal-for-intraoperative-identification-of-prostate-cancer-lesions
#27
JOURNAL ARTICLE
Anne-Claire Berrens, Malou A Sorbi, Maarten L Donswijk, Hilda A de Barros, Samaneh Azargoshasb, Matthias N van Oosterom, Daphne D D Rietbergen, Elise M Bekers, Henk G van der Poel, Fijs W B van Leeuwen, Pim J van Leeuwen
Prostate-specific membrane antigen (PSMA) PET is used to select patients with recurrent prostate cancer for metastasis-directed therapy. A surgical approach can be achieved through radioguided surgery (RGS), using a Drop-In γ-probe that traces lesions that accumulate the radioactive signal. With the aim of guiding patient selection for salvage surgery, we studied the correlation between the SUVmax of lesions on preoperative PSMA PET/CT and their intraoperative counts/s measured using the Drop-In γ-probe...
March 14, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38483586/prognostic-factors-among-patients-with-pathological-grade-group-5-prostate-cancer-based-on-robot-associated-radical-prostatectomy-specimens-from-a-large-japanese-cohort-msug94
#28
JOURNAL ARTICLE
Takeshi Sasaki, Shin Ebara, Tomoyuki Tatenuma, Yoshinori Ikehata, Akinori Nakayama, Makoto Kawase, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi, Jun Teishima, Kazuhide Makiyama, Hiroshi Kitamura, Kazutaka Saito, Takuya Koie, Fumitaka Koga, Shinji Urakami, Takahiro Inoue
PURPOSE: There are no definitive prognostic factors for patients with pathological Grade Group 5 (pGG 5) prostate cancer (PCa) undergoing robot-associated radical prostatectomy (RARP). This study aimed to explore the prognostic factors among patients with pGG 5 PCa in a large Japanese cohort (MSUG94). METHODS: This retrospective, multi-institutional cohort study was conducted between 2012 and 2021 at ten centers in Japan and included 3195 patients. Patients with clinically metastatic PCa (cN1 or cM1) and those receiving neoadjuvant and/or adjuvant therapy were excluded...
March 14, 2024: World Journal of Urology
https://read.qxmd.com/read/38482405/multivariate-logistic-regression-analysis-of-the-clinical-factors-influencing-locally-advanced-prostate-cancer
#29
JOURNAL ARTICLE
Zongpan Ke, Yan Xu, Yawei Shu, Changming Wang, Baorui Wu, Bin Zhang, Ping Xiang, Xuechun Hu
BACKGROUND: Locally advanced prostate cancer (PCa) carries a high risk of recurrence and metastasis after surgery, and the prognosis is poor. We explored the risk factors for locally advanced PCa among clinical factors (neutrophil: lymphocyte ratio, lymphocyte: monocyte ratio) and indicators of systemic inflammation [prostate-specific antigen (PSA) level, Gleason score, body mass index (BMI)] through retrospective evaluation of patients with PCa diagnosed at our center. The pathologic T stage was a key indicator of locally advanced PCa...
February 29, 2024: Translational Cancer Research
https://read.qxmd.com/read/38481869/inflammatory-myofibroblastic-tumor-of-the-genitourinary-tract-a-narrative-review
#30
REVIEW
Nikolas Moring, Daniel Swerdloff, Arkar Htoo, Mahmut Akgul, Tipu Nazeer, Badar M Mian
BACKGROUND AND OBJECTIVE: Inflammatory myofibroblastic tumor (IMT) is a rare entity that is described in several organ systems. This comprehensive review aims to identify IMTs occurring at various genitourinary (GU) organ sites and describe patterns of clinical management in adult and pediatric patients. METHODS: A comprehensive search of PubMed and Web of Science was conducted according to the Preferred Reporting Items for Systematic Review and meta-analyses statement...
February 29, 2024: Translational Andrology and Urology
https://read.qxmd.com/read/38478102/nadir-prostate-specific-antigen-after-salvage-cryotherapy-as-a-potential-prognostic-factor-for-oncologic-outcomes
#31
JOURNAL ARTICLE
E Carbonell, C Mercader, J Sureda, A Gutiérrez, J Muñoz, E Gallardo, N Feltes, J Mases, I Valduvieco, A Vilaseca, A Franco, A Alcaraz, M Musquera, M J Ribal
PURPOSE: To report oncologic outcomes of patients undergoing salvage cryotherapy (SCT) for local recurrence of prostate cancer (PCa) and to establish a nadir PSA (nPSA) value that best defines long-term oncologic success. METHODS: Retrospective study of men who underwent SCT for local recurrence of PCa between 2008 and 2020. SCT was performed in men with biochemical recurrence (BCR), after primary treatment and with biopsy-proven PCa local recurrence. Survival analysis with Kaplan-Meier and Cox models was performed...
March 13, 2024: World Journal of Urology
https://read.qxmd.com/read/38477506/significance-of-the-cribriform-morphology-area-ratio-for-biochemical-recurrence-in-gleason-score-4%C3%A2-%C3%A2-4-prostate-cancer-patients-following-robot-assisted-radical-prostatectomy
#32
JOURNAL ARTICLE
Kenji Shimodaira, Rie Inoue, Takeshi Hashimoto, Naoya Satake, Toshihide Shishido, Kazunori Namiki, Kazuharu Harada, Toshitaka Nagao, Yoshio Ohno
BACKGROUND: In prostate cancer, histological cribriform patterns are categorized as Gleason pattern 4, and recent studies have indicated that their size and percentage are associated with the risk of biochemical recurrence (BCR). However, these studies included a mixture of cases with various Gleason scores (GSs). We therefore examined the prognostic value of the area and percentage of cribriform patterns in patients with GS 4 + 4 prostate cancer. METHODS: We investigated 108 patients with GS 4 + 4 prostate cancer who underwent robot-assisted radical prostatectomy (RARP)...
March 2024: Cancer Medicine
https://read.qxmd.com/read/38477380/hypofractionated-radiation-therapy-combined-with-androgen-deprivation-therapy-for-high-risk-localized-prostate-cancer
#33
JOURNAL ARTICLE
Tae Hoon Lee, Hongryull Pyo, Gyu Sang Yoo, Seong Soo Jeon, Seong Il Seo, Byong Chang Jeong, Hwang Gyun Jeon, Hyun Hwan Sung, Minyong Kang, Wan Song, Jae Hoon Chung, Bong Kyung Bae, Won Park
INTRODUCTION: This study aimed to analyse the treatment outcomes of moderately hypofractionated radiation therapy (RT) combined with androgen deprivation therapy (ADT) and the prognostic implications of prostate-specific antigen (PSA) kinetics in high-risk localized prostate cancer. METHODS: The medical records of 140 patients who underwent definitive RT (70 Gy in 28 fractions) combined with ADT were retrospectively reviewed. ADT consists of a gonadotropin-releasing hormone agonist and an anti-androgen...
March 13, 2024: Journal of Medical Imaging and Radiation Oncology
https://read.qxmd.com/read/38476369/deep-learning-based-radiomics-model-from-pretreatment-adc-to-predict-biochemical-recurrence-in-advanced-prostate-cancer
#34
JOURNAL ARTICLE
Huihui Wang, Kexin Wang, Yaofeng Zhang, Yuke Chen, Xiaodong Zhang, Xiaoying Wang
PURPOSE: To develop deep-learning radiomics model for predicting biochemical recurrence (BCR) of advanced prostate cancer (PCa) based on pretreatment apparent diffusion coefficient (ADC) maps. METHODS: Data were collected retrospectively from 131 patients diagnosed with advanced PCa, randomly divided into training (n = 93) and test (n = 38) datasets. Pre-treatment ADC images were segmented using a pre-trained artificial intelligence (AI) model to identify suspicious PCa areas...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38473301/the-current-landscape-of-prostate-specific-membrane-antigen-psma-imaging-biomarkers-for-aggressive-prostate-cancer
#35
REVIEW
Haidar Al Saffar, David C Chen, Carlos Delgado, Jacob Ingvar, Michael S Hofman, Nathan Lawrentschuk, Marlon Perera, Declan G Murphy, Renu Eapen
The review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abilities of PSMA PET/CT for identifying both nodal and distant PCa, and its potential as a prognostic indicator for biochemical recurrence and overall survival. Additionally, we focused on the variability of PSMA's expression and its impact on personalised treatment, particularly the use of [177 Lu] Lu-PSMA-617 radioligand therapy...
February 26, 2024: Cancers
https://read.qxmd.com/read/38468864/evaluating-diagnostic-accuracy-and-inter-reader-agreement-of-the-prostate-imaging-after-focal-ablation-scoring-system
#36
JOURNAL ARTICLE
David G Gelikman, Alexander P Kenigsberg, Yan Mee Law, Enis C Yilmaz, Stephanie A Harmon, Sahil H Parikh, Jason A Hyman, Hannah Huth, Christopher R Koller, Daniel Nethala, Charles Hesswani, Maria J Merino, Sandeep Gurram, Peter L Choyke, Bradford J Wood, Peter A Pinto, Baris Turkbey
BACKGROUND AND OBJECTIVE: Focal therapy (FT) is increasingly recognized as a promising approach for managing localized prostate cancer (PCa), notably reducing treatment-related morbidities. However, post-treatment anatomical changes present significant challenges for surveillance using current imaging techniques. This study aimed to evaluate the inter-reader agreement and efficacy of the Prostate Imaging after Focal Ablation (PI-FAB) scoring system in detecting clinically significant prostate cancer (csPCa) on post-FT multiparametric magnetic resonance imaging (mpMRI)...
April 2024: European urology open science
https://read.qxmd.com/read/38458259/european-association-of-urology-risk-stratification-predicts-outcome-in-patients-receiving-psma-pet-planned-salvage-radiotherapy-for-biochemical-recurrence-following-radical-prostatectomy
#37
JOURNAL ARTICLE
Sophia Scharl, Constantinos Zamboglou, Iosif Strouthos, Andrea Farolfi, Francesca Serani, Stefan A Koerber, Jürgen Debus, Jan C Peeken, Marco M E Vogel, Stephanie G C Kroeze, Matthias Guckenberger, Manuel Krafcsik, George Hruby, Louise Emmett, Nina-Sophie Schmidt-Hegemann, Christian Trapp, Simon K B Spohn, Christoph Henkenberens, Benjamin Mayer, Mohamed Shelan, Daniel M Aebersold, Reinhard Thamm, Thomas Wiegel
PURPOSE: The European Association of Urology (EAU) proposed a risk stratification (high vs. low risk) for patients with biochemical recurrence (BR) following radical prostatectomy (RP). Here we investigated whether this stratification accurately predicts outcome, particularly in patients staged with PSMA-PET. METHODS: For this study, we used a retrospective database including 1222 PSMA-PET-staged prostate cancer patients who were treated with salvage radiotherapy (SRT) for BR, at 11 centers in 5 countries...
March 6, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38457188/do-hispanic-puerto-rican-men-have-worse-outcomes-after-radical-prostatectomy-results-from-search
#38
JOURNAL ARTICLE
Lourdes Guerrios-Rivera, Jessica L Janes, Amanda M De Hoedt, Zachary Klaassen, Martha K Terris, Matthew R Cooperberg, Christopher L Amling, Christopher J Kane, William J Aronson, Jay H Fowke, Stephen J Freedland
BACKGROUND: We previously reported that outcomes after radical prostatectomy (RP) were similar among non-Hispanic Black, non-Hispanic White, and Hispanic White Veterans Affairs (VA) patients. However, prostate cancer (PC) mortality in Puerto Rican Hispanics (PRH) may be higher than in other Hispanic groups. Data focused on PRH patients is sparse; thus, we tested the association between PR ethnicity and outcomes after RP. METHODS: Analysis included men in SEARCH cohort who underwent RP (1988-2020, n = 8311)...
February 2024: Cancer Medicine
https://read.qxmd.com/read/38455715/leiomyosarcoma-of-the-prostate-report-of-two-cases-and-review-of-the-literature
#39
Ons Bettaieb, Aicha Keskes, Carmen Llacer Moscardo
INTRODUCTION: Leiomyosarcoma (LMS) of the prostate is an extremely rare and aggressive tumor that presents with nonspecific signs and symptoms. Treatment guidelines are not yet established. CASE PRESENTATION: We report two cases of LMS of the prostate. The presenting symptom was hematuria, and diagnosis was ascertained through a transurethral resection of the prostate for the 2 patients. The treatment course consisted of three courses of chemotherapy with gemcitabine and docetaxel, radical prostatectomy, and postoperative radiation therapy for the first patient and three courses of gemcitabine and radiation therapy of the prostate and the whole pelvis for the second patient...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38454138/exosomal-lncrna-xist-promotes-perineural-invasion-of-pancreatic-cancer-cells-via-mir-211-5p-gdnf
#40
JOURNAL ARTICLE
Ke Cheng, Jinjin Pan, Qinlong Liu, Yuke Ji, Liang Liu, Xiangqian Guo, Qiang Wang, Shao Li, Jinyue Sun, Miaomiao Gong, Ying Zhang, Yuhui Yuan
Perineural invasion (PNI) is an essential form of tumor metastasis in multiple malignant cancers, such as pancreatic cancer, prostate cancer, and head and neck cancer. Growing evidence has revealed that pancreatic cancer recurrence and neuropathic pain positively correlate with PNI. Therefore, targeting PNI is a proper strategy for pancreatic cancer treatment. Exosomal lncRNA derived from pancreatic cancer cells is an essential component of the tumor microenvironment. However, whether exosomal lncXIST derived from pancreatic cancer cells can promote PNI and its exact mechanism remains to be elucidated...
March 7, 2024: Oncogene
keyword
keyword
33996
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.